SAN DIEGO, Aug. 14 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. announced today that it has appointed James B. Breitmeyer, M.D., Ph.D. to the position of Executive Vice President, Development and Chief Medical Officer. The company also announced the appointment of Christopher J. Twomey to its Board of Directors.
Dr. Breitmeyer joins Cadence from Applied Molecular Evolution (AME), a wholly-owned subsidiary of Eli Lilly and Company, where he served as Chief Medical Officer since December 2001. From 2000 to 2001, Dr. Breitmeyer was President and CEO of the Harvard Clinical Research Institute. Previously, Dr. Breitmeyer held a variety of positions at the U.S. affiliate of Serono Laboratories, Inc., including Chief Medical Officer and Senior Vice President of Research and Development. Prior to Serono, he served as a scientific advisor to Immunogen, Inc. and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer received his M.D. and Ph.D. from Washington University School of Medicine and is board certified in Internal Medicine and Oncology.
Mr. Twomey is currently the Senior Vice President, Finance and Chief Financial Officer of Biosite Incorporated, a publicly traded medical diagnostic company. During his tenure at Biosite he played an integral role in its transition from a privately held company to a publicly traded company. Prior to his tenure at Biosite, which began in March 1990, Mr. Twomey worked for Ernst & Young LLP, where he served as an Audit Manager. Mr. Twomey currently serves on the board of directors of Senomyx, Inc., a biotechnology company, where he serves as Chair of the Audit Committee. He received his B.A. in business economics from the University of California at Santa Barbara.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. Cadence currently has two Phase 3 products in development, including one for the treatment of acute pain and one for the prevention of catheter-related infections.
Contacts: William R. LaRue Susan Neath SVP & Chief Financial Officer Media & Investor Relations Cadence Pharmaceuticals, Inc. Porter Novelli Life Sciences 858-436-1400 619-849-6007
Cadence Pharmaceuticals, Inc.
CONTACT: William R. LaRue, SVP & Chief Financial Officer of CadencePharmaceuticals, Inc., +1-858-436-1400; or Susan Neath, Media & InvestorRelations, Porter Novelli Life Sciences, +1-619-849-6007, for CadencePharmaceuticals, Inc.
Web site: http://www.cadencepharm.com/
